Halozyme partner J&J wins FDA nod for myeloma combo featuring ENHANZE tech
Halozyme Therapeutics (NASDAQ:HALO) shares were in focus Friday after partner Johnson & Johnson secured U.S. regulatory approval for a subcutaneous combination therapy that significantly reduces the risk of disease progression in patients with relapsed multiple myeloma.











